Targeting Two Receptors at Once: A New Strategy for Personalized Ovarian Cancer Treatment

Table of Contents

• Key Points
• Background: Why Ovarian Cancer Is So Hard to Treat
• Current Ovarian Cancer Treatments
• First-Line Therapy
• Maintenance Therapy
• Second-Line Treatment
• New and Emerging Treatments
• The Future: Receptor Co-Targeting Strategies
• How Receptor Co-Targeting Works
• Challenges and Limitations
• What This Means for Patients
• Frequently Asked Questions
• Source Information

Key Points

• Ovarian cancer is usually diagnosed late, often returns after treatment, and more than 80% of patients eventually develop resistance to platinum-based chemotherapy and PARP inhibitors.
• Receptor co-targeting is an experimental strategy using antibody-drug conjugates and engineered nanoparticles to deliver drugs through two different molecular doors on tumor cells simultaneously.
• No co-targeted drug delivery system has yet received FDA approval; the only clinically available single-receptor ADCs for ovarian cancer are mirvetuximab soravtansine and trastuzumab deruxtecan.
• Standard first-line treatment is debulking surgery followed by carboplatin plus paclitaxel, with or without bevacizumab, and may span up to 18 weeks.
• Molecular profiling of the tumor for BRCA1/2, HRD, PD-L1, FRα, and HER2 can help doctors select the most appropriate targeted therapies.

Background: Why Ovarian Cancer Is So Hard to Treat

Ovarian cancer is a highly lethal disease. Most patients who are newly diagnosed initially go into remission after treatment. However, more than 80% eventually develop resistance to platinum-based chemotherapy and to a class of drugs called poly(ADP-ribose) polymerase (PARP) inhibitors. These high rates of acquired resistance and disease recurrence continue to complicate clinical management and limit long-term treatment benefit.

Ovarian cancer is not a single disease. It is a molecularly heterogeneous disease, meaning that tumors can differ greatly from one patient to another at the genetic and molecular level. It includes several histological subtypes (types based on how the cancer cells look under a microscope). These subtypes include:

• High-grade serous ovarian cancer (HGSOC) — the most common and most aggressive form
• Endometrioid carcinoma
• Clear cell carcinoma
• Mucinous carcinoma

Each subtype has distinct genomic landscapes (patterns of genetic changes), biological behaviors, and therapeutic vulnerabilities (weaknesses that treatments can exploit).

This challenge is particularly pronounced in HGSOC, which accounts for approximately 70% of all ovarian cancer cases. HGSOC is characterized by frequent and persistent relapse. As a result, HGSOC remains the predominant focus of investigations into novel targeted therapeutic strategies. Despite these efforts, five-year survival rates for patients with advanced-stage disease remain below 45%.

To address these poor outcomes, combination chemotherapy has been established as the standard of care. The most notable regimen is carboplatin and paclitaxel. This combination represents a prototypical dual-targeting strategy. It exploits a synergistic mode of action (the two drugs work together to produce a greater effect than either would alone) to enhance the initial tumor reduction.

Despite improved early responses, relapses remain common. This underscores the persistent barriers to durable disease control. Current approaches remain challenged by severe dose-limiting toxicities associated with conventional chemotherapies. Dose-limiting toxicity means that side effects prevent doctors from giving higher doses. This constraint limits the ability to deliver drug concentrations sufficient to eradicate all malignant cells during first-line and maintenance treatment.

This review critically evaluates co-targeting strategies for ovarian cancer therapy. The goals of these strategies are to improve treatment precision, overcome chemoresistance, and reduce disease recurrence. Central to this analysis is an examination of emerging experimental approaches that simultaneously inhibit complementary oncogenic pathways (cancer-driving biological pathways). These approaches also exploit molecular entry points on the tumor cell surface to enable the selective delivery of therapeutic agents.

These approaches include antibody-drug conjugates (ADCs) and ligand-functionalized nanoparticles. Ligand-functionalized nanoparticles are tiny delivery particles coated with molecules that bind specifically to cancer cells. Both approaches are engineered to enhance receptor-mediated drug uptake.

Among the diverse classes of cell-surface receptors, G protein-coupled receptors (GPCRs) are of particular interest. GPCRs are a large family of proteins on the cell surface that receive signals from outside the cell and trigger responses inside it. They are of interest because of their frequent dysregulation in ovarian cancer, their established druggability (meaning they can be targeted by drugs), and their suitability for ligand-mediated therapeutic delivery.

However, the clinical translation of actively targeted nanomedicines remains challenged by several factors. These include heterogeneous receptor expression, meaning receptors are not present at the same levels on all tumor cells. They also include difficulties in biomarker-based patient stratification, meaning selecting the right patients for the right treatment. They also include biological barriers to intratumoral drug delivery. These biological barriers include dense stromal architecture, meaning thick supportive tissue around the tumor. They also include extracellular matrix deposition, meaning buildup of structural material between cells. They also include elevated interstitial pressure, meaning high pressure inside the tumor. They also include variable tumor vascularization, meaning inconsistent blood supply to the tumor.

Cell-surface receptors represent particularly attractive therapeutic targets. They are physically accessible to circulating drugs and delivery systems. They may also exhibit aberrant expression (abnormal amounts or patterns) in ovarian cancer. Targeting pairs of frequently co-expressed cell surface antigens in ovarian cancer presents an opportunity. It allows researchers to integrate selective drug delivery with pathway co-inhibition. This can be done by co-delivering or independently delivering synergistically active payloads (drugs that work together).

Accordingly, this review highlights co-expressed ovarian cancer cell-surface receptors as candidates for co-targeting strategies. It examines the supporting evidence from gene expression and co-expression analyses. It also discusses how receptor-guided delivery platforms may be combined with synergistic therapeutic approaches to improve treatment precision and overcome resistance. Ultimately, such strategies have the potential to advance precision oncology. They may support more durable disease control in ovarian cancer by concentrating cytotoxic agents (cell-killing drugs) within malignant tissues while minimizing off-target toxicity (harm to healthy tissues).

Current Ovarian Cancer Treatments

The standard first-line treatment strategy for ovarian cancer consists of single or interval debulking surgery followed by combination therapy. Debulking surgery is an operation to remove as much tumor as possible. Interval debulking means the surgery is performed after some chemotherapy has already been given. The combination therapy includes intravenous carboplatin plus paclitaxel administration.

This standard regimen can span up to 18 weeks in duration. This includes neoadjuvant therapy (treatment given before surgery) and adjuvant therapy (treatment given after surgery). International treatment guidelines consistently list carboplatin-paclitaxel with or without the addition of bevacizumab as the preferred first-line therapeutic option.

In recent years, the use of neoadjuvant chemotherapy has increased substantially. It is now an established alternative prior to surgery for patients presenting with extensive disease burden. It is also an established alternative for patients with limited surgical fitness. It is also an established alternative for patients with low likelihood of achieving optimal cytoreduction, meaning complete removal of visible tumor.

According to updated Food and Drug Administration (FDA)-approved guidelines, platinum-taxane-based neoadjuvant chemotherapy should ideally be followed by interval cytoreductive surgery within four or fewer cycles to maximize outcomes. Accumulating evidence shows that neoadjuvant approaches yield high efficacy when applied to appropriately selected patients.

The current combined chemotherapy options extend beyond carboplatin and paclitaxel. They include regimens such as:

• BEP — bleomycin, etoposide, and cisplatin
• Gemcitabine-cisplatin
• JEB — carboplatin, etoposide, and bleomycin
• VAC — vincristine, actinomycin-D, and cyclophosphamide
• VeIP — vinblastine sulfate, ifosfamide, and cisplatin

These combinations appear in authoritative oncology drug lists. They remain appropriate for selected histologic subtypes, which highlights the heterogeneity of ovarian cancer treatments.

First-Line Therapy

The standard first-line treatment strategy for ovarian cancer consists of single or interval debulking surgery followed by combination therapy. This combination therapy includes intravenous carboplatin plus paclitaxel administration. This standard regimen can span up to 18 weeks in duration. It includes neoadjuvant and adjuvant therapy.

International treatment guidelines consistently list carboplatin-paclitaxel with or without the addition of bevacizumab as the preferred first-line therapeutic option. In recent years, the use of neoadjuvant chemotherapy has increased substantially. It is now an established alternative prior to surgery for patients presenting with extensive disease burden, limited surgical fitness, or low likelihood of achieving optimal cytoreduction.

According to updated FDA-approved guidelines, platinum-taxane-based neoadjuvant chemotherapy should ideally be followed by interval cytoreductive surgery within four or fewer cycles to maximize outcomes. Accumulating evidence shows that neoadjuvant approaches yield high efficacy when applied to appropriately selected patients.

The current combined chemotherapy options extend beyond carboplatin and paclitaxel. They include regimens such as BEP, gemcitabine-cisplatin, JEB, VAC, and VeIP. These combinations appear in authoritative oncology drug lists. They remain appropriate for selected histologic subtypes. This highlights the heterogeneity of ovarian cancer treatments.

Maintenance Therapy

Despite advances in first-line therapy, most patients will eventually relapse. This creates an urgent need for effective strategies to prolong remission or optimally avoid it. Maintenance therapy has emerged as a central component of contemporary ovarian cancer management. It is particularly important following a complete or partial response to first-line platinum-based chemotherapy.

One major strategy uses oral administration of PARP inhibitors. These include olaparib, niraparib, and rucaparib. This strategy demonstrates substantial progression-free survival benefits. Progression-free survival is the length of time during and after treatment that a patient lives with the disease without it getting worse. These benefits are especially notable in patients with BRCA-mutated or homologous recombination-deficient (HRD) tumors. BRCA mutations are inherited changes in genes that normally help repair DNA. HRD means the tumor has a reduced ability to repair damaged DNA. These features make PARP inhibitors key agents in biomarker-directed care.

Additionally, anti-angiogenic vascular endothelial growth factor (VEGF) inhibitors such as bevacizumab (Avastin) may be continued as maintenance following their use in the frontline chemotherapy regimen. Angiogenesis means the growth of new blood vessels that feed tumors. This approach is supported by guideline recommendations emphasizing their role in extending disease control.

These FDA-approved maintenance therapies significantly improve outcomes. They reflect the broader evolution toward personalized, molecularly informed precision treatment strategies in ovarian cancer.

Key standards and emerging combination regimens used in ovarian cancer are summarized in the original article's Table 1. That table provides details on the setting, disease context, and supporting evidence. The table includes:

• Standard chemotherapy: Paclitaxel plus carboplatin for first-line therapy in newly diagnosed epithelial ovarian cancer
• Standard combinations (FDA listed): BEP, carboplatin-paclitaxel, gemcitabine-cisplatin, JEB, PEB, VAC, and VeIP, commonly used as first-line therapy for various ovarian cancer histologies depending on the regimen
• Bevacizumab combination: Paclitaxel plus carboplatin plus bevacizumab for first-line therapy in high-risk advanced epithelial ovarian cancer
• PARP monotherapy: Rucaparib as maintenance for first-line maintenance in HRD-positive settings, or for recurrent platinum-sensitive disease
• PARP plus bevacizumab: Olaparib plus bevacizumab for first-line maintenance in HRD-positive disease after completing bevacizumab-containing chemotherapy
• PARP inhibitor combinations: Carboplatin-paclitaxel with or without bevacizumab plus pembrolizumab, then olaparib plus pembrolizumab (KEYLYNK-001) for first-line therapy in BRCA-wild-type or HRD-selected epithelial ovarian cancer
• Niraparib plus bevacizumab; olaparib plus cediranib: For maintenance or recurrent settings in HRD-positive or molecularly enriched subsets
• Bevacizumab combination: Pembrolizumab plus paclitaxel with or without bevacizumab for second-line or later treatment of platinum-resistant epithelial ovarian cancer
• ADC: Mirvetuximab soravtansine for second-line or later treatment of platinum-resistant, FRα-high-grade serous ovarian cancer
• Trastuzumab deruxtecan: For second-line or later treatment of HER2-positive ovarian cancer
• Targeted combinations (emerging): Avutometinib plus defactinib (kinase inhibitor) for recurrent low-grade serous ovarian cancer, including KRAS-mutant tumors
• Rigosertib plus PI3K/mTOR inhibitors: In early-phase clinical trials for molecularly selected ovarian tumors
• New and emerging treatments: CRLX101 in early-phase clinical trials (NCT01652079) for recurrent epithelial ovarian cancer
• Irinotecan liposome plus bevacizumab: In Phase II clinical trials (NCT04753216) for platinum-resistant, recurrent ovarian cancer

Second-Line Treatment

Second-line therapy is essential when patients relapse after first-line and maintenance treatment. At this stage, the disease is characterized by persistent recurrence due to chemotherapy resistance. The therapeutic landscape for recurrent disease is increasingly defined by targeted intervention.

The rise in ADCs has been one of the most significant developments in ovarian cancer treatment. Mirvetuximab soravtansine targets folate receptor-α (FRα). It has emerged as a major advance in platinum-resistant FRα-positive epithelial ovarian cancer. This ADC consists of an FRα-specific monoclonal antibody linked to the thiol-containing maytansine derivative (DM4). DM4 is a potent microtubule-disrupting cytotoxic payload. Microtubules are structural components of cells that are essential for cell division. The antibody component selectively binds FRα-overexpressing ovarian cancer cells. The ADC is then internalized (taken into the cell). Inside the cell, it releases DM4 to induce cell death.

The approval of mirvetuximab soravtansine was supported by the landmark Phase III MIRASOL trial. In this trial, the drug demonstrated superiority over investigator-choice single-agent chemotherapy. The comparison chemotherapies were paclitaxel, pegylated liposomal doxorubicin, or topotecan. This superiority was shown in patients with platinum-resistant FRα-positive disease.

In parallel, trastuzumab deruxtecan (T-DXd) has expanded therapeutic possibilities for human epidermal growth factor receptor 2 (HER2)-positive ovarian cancers. This reflects broader momentum for ADCs across solid tumors.

Beyond single-agent ADCs, combination strategies have expanded options for platinum-resistant disease. One example is the use of the programmed death-1 (PD-1) inhibitor pembrolizumab in conjunction with paclitaxel, with or without bevacizumab. This approach is shown in the second-line setting.

Emerging kinase inhibitors have redefined the therapeutic options for molecularly distinct ovarian cancer subsets in the recurrent setting. Kinases are enzymes that play key roles in cell signaling. Among these emerging agents are avutometinib and defactinib.

Avutometinib is a dual RAF/MEK pathway inhibitor. It targets the mitogen-activated protein kinase (MAPK) cascade, a signaling pathway that drives cancer cell growth. Defactinib is a selective focal adhesion kinase (FAK) inhibitor. These agents have shown promising activity in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated recurrent low-grade serous ovarian cancer. This subtype is often resistant to conventional chemotherapy. These agents are now being evaluated in the clinic as a targeted treatment approach.

This combination simultaneously suppresses MAPK pathway activation through RAF/MEK inhibition. It also reduces tumor-stromal signaling mediated by FAK. This aligns with contemporary precision-oncology strategies tailored to pathway dysregulation.

Early-phase studies are also assessing combinations such as rigosertib with phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitors. These aim to overcome therapeutic resistance by simultaneously disrupting RAS pathway-driven signaling and the PI3K/mTOR axis. Together, these kinase-based strategies highlight the rationale for multi-node pathway suppression in treatment-resistant disease.

New and Emerging Treatments

Nanotechnology-enabled delivery systems represent another key frontier. Polymeric nanoparticle conjugates such as CRLX101 are one example. In CRLX101, camptothecin is covalently linked to a cyclodextrin-PEG co-polymer. This forms self-assembling nanoparticles. These nanoparticles enhance intratumoral accumulation through prolonged circulation and the enhanced permeability-retention (EPR) effect. The EPR effect is a phenomenon where nanoparticles preferentially accumulate in tumor tissue because tumor blood vessels are leaky. These nanoparticles also achieve controlled drug release via hydrolysable linkers (chemical bonds that break down in the body to release the drug).

Importantly, these platforms do not yet incorporate active targeting ligands or antibodies. However, receptor-directed nanoparticle strategies are expected to substantially improve selectivity and clinical outcomes in the future.

Additional nano-constructs have progressed into early phase clinical trials. These include lipid- or polymer-based carriers designed to co-deliver chemotherapy, PARP inhibitors, siRNAs, or cytokines. In these trials, safety, pharmacokinetics (how the body processes the drug), and preliminary antitumor activity are being evaluated. These evaluations will guide future disease-specific applications.

For instance, a phase II trial is also evaluating irinotecan liposome plus bevacizumab in recurrent, platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer.

Single-agent immune checkpoint inhibitors show limited effects in epithelial ovarian cancer. However, they are promising as combination therapies with PARP inhibitors and anti-angiogenic agents. A recent example is pembrolizumab plus paclitaxel, with or without bevacizumab, for PD-L1-positive platinum-resistant disease. This was studied in the KEYNOTE-B96 trial, which has recently received FDA approval.

In addition, durvalumab (a PD-L1 inhibitor) and tremelimumab (a CTLA-4 inhibitor) have been evaluated across different clinical stages. These evaluations assess their synergy with PARP inhibitors and anti-angiogenic maintenance regimens. The goal is to overcome the immunosuppressive tumor microenvironment (a tumor environment that suppresses the body's immune response against cancer).

Cell-based approaches add a further layer of innovation. Chimeric antigen receptor (CAR) T-cell trials targeting mesothelin, FRα, and HER2 have passed proof-of-concept stages. CAR T-cell therapy involves engineering a patient's own immune cells to recognize and attack cancer cells. However, as of early 2026, no CAR-T cell therapy has been approved by the FDA for ovarian cancer treatment. This may reflect major translational obstacles with this approach, such as tumor penetration, antigen heterogeneity, and toxicity.

While their therapeutic impact remains uncertain for ovarian cancer, CAR-T cell studies continue to validate cell-surface antigens. These antigens may be exploited for the design of ADCs and ligand-functionalized nanoparticles.

The Future: Receptor Co-Targeting Strategies

Despite the clinical utility of current combination therapies and ADCs, ovarian cancer remains notoriously difficult to treat. This is due to its high intratumoral heterogeneity (the tumor contains many different types of cancer cells) and adaptive resistance (the tumor finds new ways to evade treatment). Overcoming these barriers requires the specific delivery of more than one anticancer agent into the target cells.

For example, by co-targeting two distinct cancer pathways, with payloads delivered via two different surface receptors, it may be possible to bypass resistance networks and achieve synthetic lethality. Synthetic lethality occurs when two separate defects together cause cell death, while either defect alone does not. However, executing this complex strategy requires a personalized approach. This approach must select the optimal targeting receptors and matching drugs to be loaded into engineered nanomedicines.

The original article's Figure 2 illustrates the transition from classical chemotherapy to targeted small molecules, and more recently established or experimental platforms. Some of these platforms harbor the potential for future co-targeting strategies.

How Receptor Co-Targeting Works

The combination of carboplatin and paclitaxel demonstrated profound tumor regression. This regression was driven by the concurrent disruption of distinct molecular mechanisms. While pathway inhibition strategies effectively block intracellular signaling, receptor co-targeting represents a paradigm shift. It exploits overexpressed cell surface receptors not for inhibition but as molecular entry points to enhance precision chemotherapy delivery.

A multi-layered targeting strategy can be achieved through the simultaneous delivery of synergistically acting small-molecule inhibitors. These are delivered using several cellular entry points via co-receptor targeting. The suggested approach may include a combination of classic chemotherapy and targeted therapies.

Novel strategies need to be specifically designed to intensify therapeutic pressure. This is done through the dual targeting of cell surface receptors with ADCs and surface-decorated and drug-loaded nanoparticles. During maintenance therapy, PARP and kinase inhibitors may play central roles in increasing the therapeutic pressure. This suppresses residual resistant clones that survive frontline treatment.

Collectively, these layered strategies aim to eradicate the remaining tumor cells. They do this by selectively achieving higher therapeutic concentrations within the cancer cells and the tumor microenvironment. This prevents tumor recurrence while minimizing toxicity to healthy tissues.

Receptor co-targeting drug delivery systems (DDSs) are rapidly advancing in ovarian cancer and beyond. This progress is driven by bispecific ADCs, multi-epitope/multi-payload ADCs, dual-antigen cell therapies, and emerging dual-ligand nanocarriers. Bispecific ADCs can bind to two different targets. Multi-epitope/multi-payload ADCs can recognize multiple markers and deliver multiple drugs. Dual-antigen cell therapies can recognize two different antigens. Dual-ligand nanocarriers are nanoparticles decorated with two different targeting molecules.

However, no co-targeted DDS has yet received FDA approval. Mirvetuximab soravtansine and trastuzumab deruxtecan remain the only clinically available single-receptor ADCs for ovarian cancer. This gap highlights the need for next-generation platforms to address receptor heterogeneity.

Challenges and Limitations

The strategies outlined in this review are very promising for advancing precise and personalized treatment strategies for ovarian cancer. However, dual-receptor approaches remain largely investigational. They have limited preclinical validation (testing in laboratory and animal studies before human trials).

Their clinical translation is challenged by several factors:

• Receptor heterogeneity — receptors are not present at the same levels on all tumor cells, making it difficult to target all cancer cells effectively
• Uncertain tumor selectivity — it is difficult to ensure that the treatment targets only cancer cells and not healthy cells
• Potential off-target effects — the treatment may affect healthy tissues, causing side effects
• Inefficient delivery due to tumor-microenvironment barriers — dense stromal architecture, extracellular matrix deposition, elevated interstitial pressure, and variable tumor vascularization can prevent drugs from reaching tumor cells

Furthermore, manufacturing, safety, and regulatory requirements need to be addressed. Developing these complex therapies at scale, ensuring they are safe for patients, and meeting regulatory standards are significant challenges that must be overcome before these treatments can reach the clinic.

What This Means for Patients

For patients with ovarian cancer, the research described in this review offers both hope and important context. The current standard treatments, including carboplatin-paclitaxel chemotherapy, PARP inhibitors, and bevacizumab, have significantly improved outcomes for many patients. However, the high rates of recurrence and resistance mean that new approaches are urgently needed.

Receptor co-targeting represents a promising future direction. By using two molecular "doors" to deliver cancer-killing drugs, this approach could potentially:

• Improve tumor coverage by targeting more cancer cells
• Reduce damage to healthy tissues by delivering drugs more precisely
• Overcome drug resistance by attacking cancer through multiple mechanisms simultaneously
• Enable personalized treatment based on each patient's specific tumor receptor profile

However, patients should understand that these strategies are still in early stages of development. No co-targeted drug delivery system has yet received FDA approval. The only clinically available single-receptor ADCs for ovarian cancer are mirvetuximab soravtansine and trastuzumab deruxtecan.

Patients who are interested in these emerging approaches may want to discuss clinical trial options with their healthcare team. Clinical trials are research studies that test new treatments in patients. They offer access to promising new therapies before they are widely available. The original article references several ongoing trials, including NCT01652079 (CRLX101) and NCT04753216 (irinotecan liposome plus bevacizumab).

It is also important for patients to know that molecular profiling of their tumor is becoming increasingly important. Molecular profiling involves testing the tumor for specific genetic and molecular features. This information helps doctors select the most appropriate targeted therapies. Biomarkers such as BRCA1/2 mutation status, homologous recombination deficiency (HRD), PD-L1 expression, FRα levels, and HER2 status can guide treatment decisions.

The evolution toward personalized, molecularly informed precision treatment strategies in ovarian cancer is already underway. While receptor co-targeting remains investigational, it represents a logical next step in this evolution. As research continues, patients can expect to see more targeted and personalized treatment options become available.

Frequently Asked Questions

What is receptor co-targeting for ovarian cancer?

It is an experimental strategy that uses antibody-drug conjugates and specially engineered nanoparticles to deliver cancer-killing drugs through two different molecular doors on tumor cells at the same time. The goal is to improve tumor coverage, reduce damage to healthy tissue, and help overcome drug resistance. These approaches are still largely experimental and have not received FDA approval.

Is receptor co-targeting available to patients now?

No. No co-targeted drug delivery system has yet received FDA approval. The only clinically available single-receptor antibody-drug conjugates for ovarian cancer are mirvetuximab soravtansine and trastuzumab deruxtecan. Receptor co-targeting remains investigational, with limited preclinical validation, and faces challenges in manufacturing, safety, and regulatory requirements before it can reach the clinic.

What does it mean that more than 80% of ovarian cancer patients develop resistance to platinum chemotherapy?

It means that in most patients who are newly diagnosed and initially go into remission after treatment, the cancer eventually stops responding to platinum-based chemotherapy and to PARP inhibitors. This high rate of acquired resistance and disease recurrence complicates clinical management and limits long-term treatment benefit, which is why new approaches are urgently needed.

What is the standard first-line treatment for ovarian cancer?

The standard first-line strategy is single or interval debulking surgery followed by combination therapy with intravenous carboplatin plus paclitaxel, which can span up to 18 weeks. International guidelines list carboplatin-paclitaxel with or without bevacizumab as the preferred first-line option. Neoadjuvant chemotherapy before surgery is an established alternative for some patients.

What maintenance therapy options exist after first-line treatment?

Maintenance therapy is used after a complete or partial response to first-line platinum-based chemotherapy. It includes oral PARP inhibitors such as olaparib, niraparib, and rucaparib, which show progression-free survival benefits, especially in patients with BRCA-mutated or homologous recombination-deficient tumors. Bevacizumab may also be continued as maintenance following its use in the frontline regimen.

What are the risks or limitations of receptor co-targeting?

Challenges include receptor heterogeneity, meaning receptors are not present at the same levels on all tumor cells; uncertain tumor selectivity; potential off-target effects on healthy tissues; and inefficient delivery due to tumor-microenvironment barriers such as dense stromal architecture, extracellular matrix deposition, elevated interstitial pressure, and variable tumor vascularization. Manufacturing, safety, and regulatory requirements also need to be addressed.

How can molecular profiling of my tumor guide treatment?

Molecular profiling involves testing the tumor for specific genetic and molecular features. Biomarkers such as BRCA1/2 mutation status, homologous recombination deficiency, PD-L1 expression, FRα levels, and HER2 status can guide treatment decisions. This information helps doctors select the most appropriate targeted therapies. Molecular profiling is becoming increasingly important in ovarian cancer care.

When should a patient with recurrent or platinum-resistant ovarian cancer seek a second opinion?

A second opinion is worth considering when ovarian cancer recurs or becomes resistant to platinum-based chemotherapy, since more than 80% of patients eventually develop resistance to platinum agents and PARP inhibitors. At that point, options include single-receptor antibody-drug conjugates such as mirvetuximab soravtansine and trastuzumab deruxtecan, and clinical trials of experimental approaches. Molecular profiling of the tumor — including BRCA1/2 status, homologous recombination deficiency, PD-L1 expression, FRα levels, and HER2 status — helps guide which targeted therapies fit. Discussing clinical trial options with an oncology team is reasonable. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Receptor Co‑targeting Strategies for Personalized Ovarian Cancer Therapy.

Authors: Rajapaksha W, Eldi P, Gillam TA, Blencowe A, Garg S, Albrecht H, Khetan R.

Author affiliations: Centre for Pharmaceutical Innovation (CPI), School of Pharmacy and Biomedical Science, College of Health, Adelaide University, Adelaide, SA, Australia; Whimsical Interdisciplinary Laboratory of Discovery (WILD) Research Group, School of Mathematics, Statistics, Chemistry and Physics, Murdoch University, Murdoch, Western Australia, Australia; Applied Chemistry and Translational Biomaterials (ACTB) Group, Centre for Pharmaceutical Innovation (CPI), School of Pharmacy and Biomedical Science, College of Health, Adelaide University, Adelaide, SA, Australia

Corresponding authors: Hugo Albrecht; Riya Khetan, Centre for Pharmaceutical Innovation (CPI), School of Pharmacy and Biomedical Science, College of Health, Adelaide University, Adelaide, SA, Australia. Email: hugo.albrecht@adelaide.edu.au; riya.khetan@adelaide.edu.au

Journal: International Journal of Nanomedicine

Publication details: 2026; Volume 21, Article 633450. DOI: 10.2147/IJN.S633450

Article type: Review article (Open Access)

Keywords: dual targeting, ovarian cancer, nanomedicine, active targeting, precision therapy

Received: 17 June 2026; Accepted: 26 August 2026; Published: 7 September 2026

This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace consultation with a qualified healthcare professional. Patients should discuss their individual treatment options with their oncology team.